Human IgG antibody Laboratories manufactures the sars test panel reagents distributed by Genprice. The Sars Test Panel reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Test. Other Sars products are available in stock. Specificity: Sars Category: Test Group: Panel
Typhoid IgG and IgM (S. typhi IgG + IgM) Rapid Test Kit |
|
Abbexa |
100 µl |
EUR 650 |
Typhoid IgG and IgM (S. typhi IgG + IgM) Rapid Test Kit |
|
Abbexa |
1 ml |
EUR 7200 |
Typhoid IgG and IgM (S. typhi IgG + IgM) Rapid Test Kit |
|
Abbexa |
200 µl |
EUR 2100 |
Human Tuberculosis IgG (TB IgG) Rapid Test Kit |
|
Abbexa |
100 µl |
EUR 225 |
Human Tuberculosis IgG (TB IgG) Rapid Test Kit |
|
Abbexa |
1 ml |
Ask for price |
Human Tuberculosis IgG (TB IgG) Rapid Test Kit |
|
Abbexa |
200 µl |
EUR 350 |
Human Toxoplasma IgG (TOXO IgG) Rapid Test Kit |
|
Abbexa |
100 µl |
EUR 225 |
Human Toxoplasma IgG (TOXO IgG) Rapid Test Kit |
|
Abbexa |
1 ml |
Ask for price |
Human Toxoplasma IgG (TOXO IgG) Rapid Test Kit |
|
Abbexa |
200 µl |
EUR 350 |
Human Cytomegalovirus IgG (CMV IgG) Rapid Test Kit |
|
Abbexa |
100 µl |
EUR 225 |
Human Cytomegalovirus IgG (CMV IgG) Rapid Test Kit |
|
Abbexa |
1 ml |
Ask for price |
Human Cytomegalovirus IgG (CMV IgG) Rapid Test Kit |
|
Abbexa |
200 µl |
EUR 350 |
Panel information
anti- SARS antibody |
|
FNab07609 |
FN Test |
100µg |
EUR 658.5 |
|
|
|
Description: Antibody raised against SARS |
SARS-CoV-2 Variants Total IgG 6-plex Panel (Flow Cytometry Multiplex Bead Assay) |
|
FCM-B01R |
ACROBIOSYSTEMS |
96tests |
EUR 1209.9 |
|
|
|
Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a multiplex serological test for assessing antibody responses to mutant strains is in urgent need. |
SARS-CoV-2 Antigen Rapid Test Kit |
|
CoV2Ag-1 |
UnScience |
1T |
EUR 9.6 |
|
|
|
Description: This kit adopts the sandwich method and the technical principle of colloidal gold immunochromatography to qualitative determine the SARS-CoV-2 antigen. During the test, the sample is dropped into the sample well, and chromatography is performed under the capillary effect. The SARS-CoV-2 antigen in the sample combined with the colloidal goldlabeled SARS-CoV-2 monoclonal antibody I, and then spread to the test area. It is captured by another coated antibody (SARS-CoV-2 monoclonal antibody II), to form a complex and gather in the test area (T line). The quality control area is coated with the goat antimouse antibody, and the colloidal gold-labeled antibody is captured to form a complex and aggregate in the quality control area (C line). If the C line does not show color, it indicates that the result is invalid, and this sample needs to be tested again. |
SARS-CoV-2 Antigen Rapid Test Kit |
|
CoV2Ag-25 |
UnScience |
25T/kit |
EUR 42 |
|
|
|
Description: This product is used for in vitro qualitative detection of SARS-CoV-2 antigen in human oropharyngeal swabs, nasal swabs and nasopharyngeal swabs. It is helpful as an aid in the screening of early mild, asymptomatic, or acute patients for identification of SARS-CoV-2 infection. |
SARS-CoV-2 Rapid Antigen Test Nasal |
|
9901-NCOV-03G |
Roche Diagnostics |
25 Tests/Kit |
EUR 112.8 |
|
|
|
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke |
Mouse SARS-CoV-2 Variants Total IgG 6-plex Panel (Flow Cytometry Multiplex Bead Assay) |
|
FCM-B02R |
ACROBIOSYSTEMS |
96tests |
EUR 1209.9 |
|
|
|
Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a multiplex serological test for assessing antibody responses to mutant strains is in urgent need. |
SARS-CoV-2 Variants Neutralizing Antibody 6-plex Panel (Flow Cytometry Multiplex Bead Assay) |
|
FCM-N04R |
ACROBIOSYSTEMS |
96tests |
EUR 1209.9 |
|
|
|
Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a multiplex serological test for assessing antibody responses to mutant strains is in urgent need. |
SARS-CoV-2 Omicron Sublineages Total IgG 6-plex Panel (Flow Cytometry Multiplex Bead Assay) |
|
FCM-B18R |
ACROBIOSYSTEMS |
96tests |
EUR 1209.9 |
|
|
|
Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a high-throughput assay to measure IgG antibodies against the mutants is in urgent need. |
SARS-CoV-2 Variants Total IgG 6-plex Panel (Flow Cytometry Multiplex Bead Assay, Non-premixed) |
|
FCM-B08R |
ACROBIOSYSTEMS |
96tests |
EUR 1209.9 |
|
|
|
Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a multiplex serological test for assessing antibody responses to mutant strains is in urgent need. |
SARS-CoV-2 Omicron Subvariants Neutralizing Antibody 5-plex Panel (Flow Cytometry Multiplex Bead Assay) |
|
FCM-N06R |
ACROBIOSYSTEMS |
96tests |
EUR 1209.9 |
|
|
|
Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide. Omicron is a variant of SARS-CoV-2 first detected in November 2021 and is causing the ongoing COVID-19 pandemic. The Omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. Its recent descendants BA.2.12.1 and BA.4/5 have surged dramatically to become dominant in the United States and South Africa, respectively. BA.2.12.1 and BA.4/BA.5 exhibit comparable ACE2-binding affinities to BA.2. Importantly, BA.2.12.1 and BA.4/BA.5 display stronger neutralization evasion than BA.2 against the plasma from 3-dose vaccination and, most strikingly, from post-vaccination BA.1 infections. |
